ReviewMicroorganisms2020
Viral Vector Vaccines against Bluetongue Virus.
Review in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Protective Efficacy of Vaccines Against Grass Carp Hemorrhagic Disease: A Systematic Review and Meta-Analysis.Journal of fish diseases · 2026Pooled it
- Expression of bluetongue virus core proteins VP2 and VP7 by bovine herpesvirus-4 confers protection against virulent challenge in a mouse model.Veterinary research · 2026Article
- Article
- Bluetongue in ruminants: Global epidemiology, pathogenesis, and advances in diagnostic and control strategies within a One Health framework.Veterinary world · 2025Review
- Spatiotemporal Dynamics of Emerging Foot-and-Mouth Disease, Bluetongue, and Peste Des Petits Ruminants in Algeria.Viruses · 2025Article
- High seroprevalence and age-associated dynamics of bluetongue and epizootic hemorrhagic disease viruses in North American bison (Frontiers in veterinary science · 2025Article
- The MVA-VP2-NS1-2A-NS2-Nt vaccine candidate provides heterologous protection in sheep against bluetongue virus.Frontiers in immunology · 2025Article
- Article
- Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(-/-) mice.Journal of virology · 2024Article
- In Silico Development of a Multi-Epitope Subunit Vaccine against Bluetongue Virus inPathogens (Basel, Switzerland) · 2024Article
- Article
- Engineering recombinant replication-competent bluetongue viruses expressing reporter genes forMicrobiology spectrum · 2024Article
- Estimation of the economic impact of a bluetongue serotype 4 outbreak in Tunisia.Frontiers in veterinary science · 2024Article
- Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.Frontiers in immunology · 2024Article
- IFNAR(-/-) Mice Constitute a Suitable Animal Model for Epizootic Hemorrhagic Disease Virus Study and Vaccine Evaluation.International journal of biological sciences · 2024Article
- Epizootic Hemorrhagic Disease Virus: Current Knowledge and Emerging Perspectives.Microorganisms · 2023Review
- Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.Vaccines · 2022Review
- Vector-Borne Viral Diseases as a Current Threat for Human and Animal Health-One Health Perspective.Journal of clinical medicine · 2022Review
- The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2Journal of virology · 2022Article
- Vaccination as a Strategy to Prevent Bluetongue Virus Vertical Transmission.Pathogens (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Bluetongue virus (BTV), the prototype member of the genus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.